Ose Immunotherapeutics SA represents a strong commitment to innovative immunotherapy solutions. The company's corporate philosophy revolves around the development of breakthrough medicines to treat immunotherapy-related diseases. With a focus on harnessing the power of the immune system, Ose Immunotherapeutics SA aims to provide effective and safe treatment options for patients. By combining cutting-edge research and clinical expertise, the company strives to address unmet medical needs and improve patient outcomes. Ose Immunotherapeutics SA's dedication to scientific excellence and patient-centric approach makes it a leader in the field of immunotherapy.

Ose Immunotherapeutics SA is primarily present in France, where its headquarters is located in Nantes. The company is a biotechnology firm focused on the development of immunotherapies for the treatment of immune-related diseases and cancer. With a strong presence in France, Ose Immunotherapeutics SA aims to expand its reach globally by establishing collaborations and partnerships with various countries and regions.

Some significant milestones achieved by Ose Immunotherapeutics SA include the successful completion of a Phase 1 clinical trial for their innovative cancer immunotherapy product, OSE-127, in patients with autoimmune diseases. The company also obtained positive initial clinical results for their lead product candidate, Tedopi®, in lung cancer patients. Additionally, Ose Immunotherapeutics SA secured strategic partnerships and collaborations with global pharmaceutical companies for the development and commercialization of their immunotherapy pipeline. These milestones demonstrate the company's progress in advancing novel immunotherapeutic treatments and establishing valuable industry partnerships in their mission to improve patient outcomes.

Ose Immunotherapeutics SA is a biotechnology company specializing in immunotherapy. Founded in 2012, the company is based in Nantes, France. Ose Immunotherapeutics focuses on developing innovative therapeutic solutions to fight against cancer and autoimmune diseases. With a strong emphasis on research and development, the company utilizes its expertise in immunology and drug development to advance its proprietary pipeline of novel immunotherapies. Ose Immunotherapeutics has established collaborations with renowned academic institutions and pharmaceutical companies to further enhance its scientific capabilities and bring groundbreaking treatments to patients in need.

The main competitors of Ose Immunotherapeutics SA in the market include global biopharmaceutical companies such as Bristol Myers Squibb, Merck & Co., Inc., and Novartis AG. These companies are active in the field of immunotherapy and aim to develop effective treatments for various diseases. Ose Immunotherapeutics SA faces competition in terms of research and development efforts, as well as commercialization strategies, as these competitors also strive to bring innovative immunotherapeutic products to the market.

Ose Immunotherapeutics SA, a leading company in the biotechnology sector, mainly operates in the field of immunotherapy. With a focus on developing innovative immunotherapies to fight cancer and autoimmune diseases, Ose Immunotherapeutics utilizes its deep understanding of the immune system to create groundbreaking treatments. By leveraging its expertise in deciphering the complex interactions between the immune system and diseases, the company aims to revolutionize the way these conditions are treated. Ose Immunotherapeutics' primary industry involvement lies in the biotechnology sector, specifically focused on immunotherapy.

The business model of Ose Immunotherapeutics SA is focused on developing and commercializing immunotherapies for the treatment of various types of cancer. The company specializes in harnessing the power of the immune system to target and eliminate cancer cells. Ose Immunotherapeutics SA aims to develop innovative and personalized immunotherapies that can improve patient outcomes and provide more effective and targeted treatment options. By leveraging its expertise in immunology and biotechnology, the company is dedicated to advancing the field of cancer immunotherapy and ultimately helping patients overcome this devastating disease.

OSE Immunotherapeutics KGV ir 2,96.

OSE Immunotherapeutics KUV ir 1,88.

AlleAktien kvalitātes vērtējums OSE Immunotherapeutics ir 4/10.

gaidāmā OSE Immunotherapeutics apgrozījums ir 78,60 milj. EUR.

gaidāmā OSE Immunotherapeutics peļņa ir 49,98 milj. EUR.

Ose Immunotherapeutics SA is a French company specialized in the discovery and development of new therapies for the treatment of cancer and autoimmune diseases. The company uses its unique technology platform to identify and develop immune-modulating drugs that can activate or suppress the immune system. The business model of Ose Immunotherapeutics is based on three pillars: the discovery and development of new therapies, collaboration with partner companies, and business development through the use of its technology platform. 1. Discovery and development of new therapies: Ose Immunotherapeutics is working on identifying and developing new drugs that can influence the immune system and combat diseases. The company focuses on two main areas: cancer immunotherapy and immunomodulation in autoimmune diseases. In the field of cancer immunotherapy, Ose Immunotherapeutics has developed a variety of promising antibodies that can specifically target and attack certain receptors on cancer cells. By blocking these receptors, the immune system can be activated to fight against the cancer cells. In the field of immunomodulation, the company is working on new therapies for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, or psoriasis. 2. Collaboration with partner companies: Ose Immunotherapeutics has formed strategic partnerships with various companies in the pharmaceutical and biotech industry. This collaboration allows the company to use its technology platform for the joint development of new therapies. Additionally, Ose Immunotherapeutics gains access to the resources, expertise, and network of its partners to expedite the market introduction of its products. 3. Business development through the use of the technology platform: Ose Immunotherapeutics has developed a unique technology platform that enables the rapid identification and development of new drugs. The platform is based on the use of antibodies and peptides to influence the immune system. By utilizing this technology platform, Ose Immunotherapeutics can develop new products faster and more cost-effectively than traditional development processes. Ose Immunotherapeutics currently has three promising drugs in various stages of clinical development: 1. Tedopi (OSE-2101): A novel immune-modulating cancer vaccine used in the treatment of advanced non-small cell lung cancer. The vaccine strengthens the immune system to specifically recognize and kill cancer cells. 2. Effi-7: An antibody targeting the CD6 receptor that can be used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, or Crohn's disease. 3. OSE-127: An antibody targeting the interleukin-7 receptor molecule developed for the treatment of autoimmune diseases and cancer. Overall, the business model of Ose Immunotherapeutics is focused on the development and commercialization of innovative immunotherapies that have the potential to revolutionize the treatment of cancer and autoimmune diseases. With its unique technology platform and strategic partnerships, Ose Immunotherapeutics is well positioned to tap into and expand the market for immunotherapies.

OSE Immunotherapeutics izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt OSE Immunotherapeutics vai uzņēmums nedod dividendes.

OSE Immunotherapeutics ISIN ir FR0012127173.

OSE Immunotherapeutics WKN ir A14QXP.

OSE Immunotherapeutics simbols ir OSE.PA.

Pēdējo 12 mēnešu laikā OSE Immunotherapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos OSE Immunotherapeutics plāno maksāt dividendes 0 EUR apmērā.

OSE Immunotherapeutics pašreizējā dividendu rentabilitāte ir .

OSE Immunotherapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

OSE Immunotherapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

OSE Immunotherapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu OSE Immunotherapeutics apmērā 0 EUR, kas tika izmaksāta 24.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 24.09.2024..

Pēdējās dividendes izmaksa notika 24.09.2024..

Gadā 2023, OSE Immunotherapeutics izmaksāja 0 EUR dividendes.

OSE Immunotherapeutics dividendes tiek izmaksātas EUR.